Amneal Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Amneal Pharmaceuticals (AMRX) completed its acquisition of Kashiv BioSciences, aiming to become a top biosimilars player. Q2 2026 revenue rose 10% to $796M, net income doubled to $58M. Amneal raised its full-year revenue outlook to $3.10B-$3.20B. The deal adds $350M in debt and increases capex guidance to $150M. Hedge fund ownership fell, but short interest remains low.
The FDA is collaborating with six manufacturers to boost estradiol patch supply amid increased demand and access issues. Companies like Bayer, Sandoz, and Viatris are expanding production. Bayer expects temporary supply constraints until early 2027. The FDA is monitoring supply and assisting manufacturers.
Quantum Computing Inc. (QUBT) and Amneal Pharmaceuticals (AMRX) are highlighted for high insider ownership (11.2% and 38.2%) and growth potential. QUBT expects 59.2% annual revenue growth, while AMRX raised 2026 earnings guidance and reported strong Q2 results. Tutor Perini (TPC) also shows growth, with significant contracts and double-digit revenue growth guidance for 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning AMRX (Amneal Pharmaceuticals, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent AMRX coverage spans financial news, mergers & acquisitions and regulation.
In the last 30 days, AMRX insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($7.2M). The most active reporter was Daly Jason B., EVP, Chief Legal Officer, with 2 filings.
The deal expands Amneal's biosimilar platform and the guidance lift suggests stronger future cash flow.
Potential increase in production could alleviate supply constraints for Amneal's estrogen patches.
Positive earnings surprise and guidance raise upside potential.
Analyst upgrade and higher price target may lift the stock and attract new buying interest.
The gift is a neutral insider transaction with no immediate price impact.
alphai scores every news story that mentions AMRX with an AI model for sentiment and relevance, and aggregates insider trades from Amneal Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Amneal Pharmaceuticals (AMRX) completed its acquisition of Kashiv BioSciences, aiming to become a top biosimilars player. Q2 2026 revenue rose 10% to $796M, net income doubled to $58M. Amneal raised its full-year revenue outlook to $3.10B-$3.20B. The deal adds $350M in debt and increases capex guidance to $150M. Hedge fund ownership fell, but short interest remains low.
3 min readThe FDA is collaborating with six manufacturers to boost estradiol patch supply amid increased demand and access issues. Companies like Bayer, Sandoz, and Viatris are expanding production. Bayer expects temporary supply constraints until early 2027. The FDA is monitoring supply and assisting manufacturers.
2 min readQuantum Computing Inc. (QUBT) and Amneal Pharmaceuticals (AMRX) are highlighted for high insider ownership (11.2% and 38.2%) and growth potential. QUBT expects 59.2% annual revenue growth, while AMRX raised 2026 earnings guidance and reported strong Q2 results. Tutor Perini (TPC) also shows growth, with significant contracts and double-digit revenue growth guidance for 2026.
2 min readJPMorgan resumed coverage of Amneal Pharmaceuticals (AMRX) with an Overweight rating and a raised price target of $22. The firm expects sustained high-single-digit sales growth due to the company's diversified portfolio. According to JPMorgan, affordable medicines growth is accelerating.
2 min readAmneal Pharmaceuticals (AMRX) reported that EVP Andrew S. Boyer gifted 152,426 shares to a family trust on 2026-08-21. Boyer's remaining direct holdings are 273,646 shares. The gift was made at $0.00 per share.
1 min readAmneal Pharmaceuticals acquired Kashiv BioSciences, expanding its U.S. biosimilars capabilities. The deal adds a Chicago R&D and manufacturing facility, and Amneal now has over 150,000 sq. ft. of space in New Jersey. The Association for Accessible Medicines says this could strengthen domestic pharmaceutical manufacturing and increase competition in the biosimilars market.
2 min readAmylyx Pharmaceuticals shares rose 53% after its avexitide treatment met trial endpoints. Meta Platforms fell 3% amid a lawsuit. Carvana dropped 3% after director stock sales. UGI Corporation surged 12% on a $9B KKR bid report. AI-related stocks declined. Klarna fell 21% on weak guidance. Baidu dropped 12% on earnings miss. Home Depot rose slightly on earnings beat. Fabrinet fell 20% on margin concerns. Memory stocks declined. Duolingo rose 7% on an upgrade.
4 min readA peer comparison of Q2 results in generic pharmaceuticals says the four tracked companies beat analysts’ revenue consensus by 2.6% on average, but shares fell 5.6% since reporting. ANI Pharmaceuticals (ANIP) revenue was $266m (+25.9%), EPS beat, but full-year revenue guidance missed; stock down 9.1% to $75.12. Amphastar (AMPH) revenue $183.9m (+5.4%) beat; stock up 2.3% to $20.28. Viatris (VTRS) revenue $3.76b (+4.9%) beat; stock down 7.6% to $16.32. Amneal (AMRX) revenue $796.2m (+9.9%) beat;
6 min readKiely John sold 50,000 shares of Amneal Pharmaceuticals, Inc. (AMRX) at $17.64 ($0.88M total) on 2026-08-13.
2 min readAn SEC Form 4 filed Aug. 13 shows Nikita Shah, Executive Vice President of Amneal Pharmaceuticals (NASDAQ:AMRX), sold 146,403 shares for about $2.56M. The article notes AMRX shares traded around $17.05, up 1.8% in Friday morning trading, and cites recent revenue growth and higher debt-to-equity.
3 min read
